Delivery Order SPE2DB24D1205-SPE2DB24FCRDD
Award Date 5/8/24
Potential Completion Date 5/9/24
Potential Value $1.3K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Amerisourcebergen Drug Corp, through its Corporate Office division, has been awarded a $1,705.35 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) Troop Support Medical to provide XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML pharmaceutical products. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,480.22 firm fixed-price delivery order is for the XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML product. The contract has an ultimate completion date of November 18, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a...
- The Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a firm fixed price delivery order contract valued at $3,937.95 to provide XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a specialty pharmaceutical product. This delivery order is part of a larger indefinite delivery contract (IDC) valued up to $999,999,999.00 with a performance period through December 31, 2025, which serves as the primary vehicle for Amerisourcebergen Drug Corp to...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,021.23, is a Firm Fixed Price Delivery Order for the pharmaceutical product "XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML". The contract has a completion date of March 14, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award is a Delivery Order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,072.07, is for the supply of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product. The contract has a Firm Fixed Price pricing type and an ultimate completion date of March 10, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
- This is a $1,050.12 Firm Fixed Price Delivery Order awarded by the Defense Logistics Agency (DLA) Medical Supply Chain to Amerisourcebergen Drug Corp's Corporate Office Division for the supply of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML pharmaceutical products. The contract has an ultimate completion date of April 24, 2024. Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a...
- The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract worth $1,252.44 to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor. The contract is for the delivery of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a medication. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 that Amerisourcebergen holds with DLA Troop Support Medical, which serves as the primary vehicle for the company to supply a wide...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is a delivery order with a firm fixed price valued at $2,024.63, with an ultimate completion date of April 2, 2024. The contract provides for the delivery of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a specialty pharmaceutical product. Amerisourcebergen Drug...
- This federal contract award was made to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $1,547.20 firm-fixed-price delivery order is for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product, with a completion date of May 17, 2024. Amerisourcebergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML medical products. The $2,074.93 firm fixed-price contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has a completion date of November 20, 2024. The contract is not designated with a set-aside requirement. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB24FCRDDDelivery Order
This federal contract award to Amerisourcebergen Drug Corporation's Corporate Office Division is for the supply of the pharmaceutical product XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML to the Defense Logistics Agency (DLA). The $1,312.65 firm fixed-price delivery order has a completion date of May 9, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract does not have a set-aside designation.
Generated 8/7/24, 10:04 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 5/8/24 |